Clongen adds new emerging pathogens diagnostic assays to tick, arthropod-borne illness test offering.
M2 PHARMA-August 27, 2014-Clongen adds new emerging pathogens diagnostic assays to tick, arthropod-borne illness test offering
(C)2014 M2 COMMUNICATIONS
27 August 2014 - US molecular diagnostics provider Clongen Laboratories said yesterday it had had expanded its offering of tests for detecting tick and arthropod-borne ilnesses by adding new assays for identifying emerging pathogens most recently implicated in severe to fatal cases resulting from tick and other arthropod bites.
The new molecular-based tests include Borrelia miyamotoi, Borrelia hermsii, Rickettsia parkeri, Heartland Virus, Rift Valley Fever Virus, Powassan Virus. Colorado Tick Fever Virus and Chikungunya Fever Virus.
Dr. Ahmed Kilani, Clongen's president and laboratory director, said that the new tests complement the company's existing portfolio of some 20 other tick-borne pathogen assays and some 250 diagnostic assays that it has been offering since 2004.
Clongen has also developed tests for conditions that are not endemic to North America, including Malaria, Chagas Disease, Leishmaniasis, Hantavirus, Sin Nombre Virus, Dengue, in addition to many other hemorrhagic fevers caused by different viruses. Furthermore, the company will launch in December 2014 new test panels for bacterial and parasitic gastrointestinal infections, as well as gynecology/urology tests.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 27, 2014|
|Previous Article:||NuGEN unveils NGS target enrichment solution for gene fusion events detection.|
|Next Article:||Cancer Genetics' diagnostic genomic tests get included in NIH's Genetic Testing Registry.|